Description

Cardinal Health’s $1.35 Billion Buyback — A Bold Signal Behind Its Capital Strategy!

Cardinal Health, Inc. concluded fiscal year 2026 with marked financial improvements driven primarily by its Pharmaceutical and Specialty Solutions segment, which benefited from resilient demand and specialty business strength. The company reported a 6% increase in total revenue for the fourth quarter to $63.7 billion and a 14% rise for the full year to $254 billion, with operating earnings growing 30% year-over-year and earnings per share increasing by 40% in the quarter. Adjusted free cash flow reached $5 billion, reflecting strong operational execution and favorable demand across its portfolio. The Pharmaceutical segment experienced solid growth with 6% revenue expansion in Q4 and 21% profit increase, supported by steady brand and specialty portfolios alongside robust generics demand. This segment faces headwinds from recently implemented Inflation Reduction Act (IRA) pricing adjustments estimated to affect revenue growth but anticipated to have no adverse profit implications.